RxSight Third Quarter 2026 Earnings Conference Call - RXSIGHT INC

Explicit Guidance:

• Full-year 2026 financial guidance is not provided; formal guidance for 2027 (including revenue, OpEx, and pipeline milestones) is expected to be released alongside Q4 2026 results in early 2027.
• Restructuring cost savings are expected to materialize in the operating expense base starting in 2027 and beyond, positioning the company to achieve lower 2027 OPEX than 2026 levels despite incremental investments in commercial and R&D.
• Q4 2026 LAL sales are expected to be "in line with Q2 2026," implying a recovery from the Q3 dip, though competitive pressure and restructuring disruption are anticipated to persist.
• The $60 million upfront payment from the Alcon collaboration is already recognized in Q3 2026 cash balances and will not be subject to retrieval, solidifying the partnership's financial foundation.

Business-Segment Outlook:

• U.S. LAL Business: Strategy focuses on driving deeper adoption within the existing install base through high-frequency engagement, practice workflow integration, and peer-to-peer advocacy; the company expects to scale successful "pockets" of high-utilizing surgeons to the broader customer base.
• Sales Force Expansion: The U.S. sales team size has been nearly doubled; while this caused near-term disruption in Q3 due to territory remapping and onboarding, the impact is expected to build over time in late 2026 and 2027, enabling higher cadence engagement with existing accounts.
• LDD (Light Delivery Device): Strategic focus has shifted away from new LDD placements; future sales are expected to be "fairly limited" (a handful per quarter), with resources reallocated primarily to driving LAL utilization within the installed base.
• Next-Generation LAL Pipeline: Development is ongoing with a target for potential market introduction in 2028; key features include expanded patient eligibility (larger aperture), reduced workflow (fewer lock-in visits), and improved surgical design.
• Alcon Collaboration: The partnership has passed the initial 120-day milestone; the teams anticipate significant progress in bringing post-operative adjustability to the majority of the premium IOL market, with detailed milestone updates expected in 2027 guidance.
• International Operations: International focus remains intentional but is a lower priority than U.S. LAL reinvigoration, Next-Gen development, and the Alcon partnership; resource allocation to this region will be minimized relative to domestic priorities.

Market and Competitive Outlook:

• Competitive Dynamics: Continued pressure from competitors offering "free product" and sampling lenses is impacting utilization; however, management asserts that clinical data for new IOLs shows only "modest improvements" over the LAL platform, with no technology matching LAL's ability to deliver spectacle-free outcomes.
• Post-Refractive Segment: LAL remains the primary "go-to" lens for post-refractive patients; while some experimentation with competitive EAT-Off lenses (e.g., Vividi Pro) is occurring in low-risk subsets, no wholesale shift in physician preference is expected.
• Demand Trends: Cataract surgical volume is described as "slightly soft" but more stable than the first half of 2026; overall patient flow has rebounded slightly, though the broader market remains competitive with new installs.
• Pricing and ASP: Average Selling Prices (ASPs) for LDD are holding steady; the company anticipates continued use of rental options to encourage therapy adoption without significant price erosion.

Macro / Industry Outlook:

• Management does not provide specific forecasts for broader economic variables (rates, FX, tariffs), citing "economic uncertainty" in early 2026 as a past factor affecting volume, now considered more stable.
• The industry is characterized by an "increasingly competitive environment" where differentiation relies on the unique clinical value of adjustability rather than incremental technological specs.

Strategic Initiatives:

• Commercial Leadership: Appointments of Taryn Conway (Chief Commercial Officer) and Frank Shields (EVP of Sales) are driving a new commercial strategy focused on frequency, education, and workflow integration.
• Operational Restructuring: A comprehensive cost-cutting initiative affecting manufacturing, corporate functions, and international operations was completed in Q3 2026; expected savings will support long-term value creation while reducing the 2027 base expense.
• Capital Allocation: A disciplined approach is being applied to reinvest savings into the Alcon collaboration, U.S. commercial expansion, and Next-Gen R&D; the company aims to reduce total OPEX year-over-year in 2027 while increasing specific strategic spend.
• Data-Driven Execution: Implementation of rigorous KPIs to measure sales rep frequency, patient segmentation, and cohort utilization to replicate success from high-performing clinics across the broader install base.

Risks and Headwinds to Outlook:

• Competitive Activity: Continued product launches, aggressive free-product sampling, and trialing of competitive lenses pose a risk to volume and market share.
• Internal Disruption: Near-term performance may be impacted by the time required to onboard the expanded sales force, re-map territories, and integrate new leadership; management expects Q4 2026 to reflect this "near-term pain."
• Execution Risk: Success depends on the ability to consistently replicate high-utilization outcomes across the entire install base; failure to drive sufficient engagement frequency could limit growth.
• Regulatory/Pipeline: Next-Gen LAL approval remains a target rather than a certainty for 2028; any delays in regulatory pathways or clinical trial outcomes could impact future revenue inflection.

Management Tone on the Future:

• Management expresses "cautious optimism" and "confidence" in the long-term strategy, acknowledging current "near-term pain" but emphasizing the necessity of restructuring and commercial overhauling for future growth.
• There is a strong emphasis on "urgency," "discipline," and "operational rigor," with leadership expressing belief that the foundational changes (team, workflow, focus) are correctly positioned to drive long-term value despite short-term volume fluctuations.

Miscellaneous:

• No formal dividend or share buyback guidance is mentioned; the focus is on preserving cash to fund strategic initiatives while reducing OpEx.
• The company reports a net loss of $16.2 million in Q3 2026, with an adjusted net loss of $8.6 million (note: transcript likely contains a typo for $8.6 million, as $8.6 billion is inconsistent with revenue; context implies adjusted loss figure) driven by $7.6 million in stock-based compensation.